Physical Activity May Reduce Risk for Death From Cancer
via HealthDayTUESDAY, Feb. 24, 2026 -- Moderate-to-vigorous physical activity (MVPA) may lower the risk for cancer mortality among cancer survivors, according to a study published online Feb. 17 in JAMA Network Open.
Erika Rees-Punia, Ph.D., from the American Cancer Society in Atlanta, and colleagues examined whether engagement in physical activity after a cancer diagnosis is associated with longer survival. The analysis included pooled data from 17,141 individuals with a history of bladder, endometrial, kidney, lung, oral, ovarian, or rectal cancer.
The researchers found that engagement in low amounts of MVPA (>0 to <7.5 versus 0 MET-hours/week) was associated with a lower risk for cancer mortality among survivors who had been diagnosed with bladder (hazard ratio [HR], 0.67), endometrial (HR, 0.62), and lung cancer (HR, 0.56). A lower risk for cancer mortality was seen when doubling the recommended MVPA guideline or more (>15 versus 0 MET-hours/week) for survivors of oral (HR, 0.39 for >22.5 to 30.0 MET-hours/week) and rectal cancer (HR, 0.57 for >15.0 to 22.5 MET-hours/week). Even if they were inactive before their diagnosis, lung (HR, 0.58) and rectal (HR, 0.51) cancer survivors who met guidelines after diagnosis had a lower risk for cancer mortality versus those who were inactive before and after their diagnosis.
"Findings suggest that it is important for health care professionals to promote physical activity for longevity and overall health among people living with and beyond cancer," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-02-25 01:56
Read more
- Dental Guidelines Call For More Judicious Use Of X-Rays
- Plant-Based Diets May Aid Symptoms of Psoriasis
- Recommendations Developed for Primary Care Asthma Management in Veterans, Military Members
- FDA Approves Filkri (filgrastim-laha), a Biosimilar to Neupogen
- Novartis Remibrutinib First Therapy to Achieve Phase III Primary Endpoint in Chronic Inducible Urticaria (CIndU)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions